


An urgent need to institute COVID-19 testing in patients with IBD experiencing flares

Mohammed Nabil Quraishi ^{1,2}, Rachel Cooney,¹
Matthew James Brookes,³ Naveen Sharma^{1,2}

¹Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

²University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, United Kingdom

³Department of Gastroenterology, New Cross Hospital, Wolverhampton, UK

Correspondence to

Dr Mohammed Nabil Quraishi, Department of Gastroenterology, University Hospitals Birmingham NHS Foundation Trust, Birmingham B12 2TT, UK; M.N. Quraishi@bham.ac.uk

Received 19 March 2020

Accepted 22 March 2020

Published Online First

27 March 2020

We are facing unprecedented challenges during the current coronavirus disease 2019 (COVID-19) pandemic. Management of chronic diseases requiring immunosuppression, such as inflammatory bowel disease (IBD), during this time period has led to difficult and exceptional decision making by both healthcare providers and patients. Decisions with regard to starting or continuing immunosuppression in IBD in both COVID-19 confirmed and suspected patients are done on a case-by-case basis based on pragmatism and experience drawn from other infections. However, our knowledge of COVID-19 is evolving. Rapid mobilisation of efforts globally has led to expert recommendations by various medical societies to help guide clinicians.^{1,2} Furthermore, through commendable efforts made by the IBD community through international registries and regular updates there is now some relative clarity.³

IBD affects over 700 000 people in the UK and forms one of the largest groups of chronic diseases that require immunosuppressive therapies.^{4,5} It is estimated that around 50% of patients experience at least one flare annually. However, it is now evident that digestive symptoms, such as diarrhoea, are often the key presenting feature in nearly half of severe acute respiratory syndrome coronavirus 2 infected patients.^{6,7} Furthermore, diarrhoea may precede onset of any respiratory tract symptoms and is associated with poorer outcomes.

Current UK policies only allow testing for COVID-19 infection in individuals who need admission to hospital or intensive care.⁸ Patients with IBD who have a cough or fever are advised to continue

self-isolation on the presumption that their symptoms may be associated with the infection. However, in this context it is now important to consider COVID-19 infections in patients with IBD with exacerbations of their gastrointestinal symptoms. There is preliminary data to support the potential usage of low-dose corticosteroids in the treatment of respiratory coronavirus infections, including COVID-19, severe acute respiratory syndrome and the Middle East respiratory syndrome, through a modulation of the immune response, but this is specific to cases of severe acute respiratory coronavirus and acute lung injury or adult respiratory distress syndrome.^{9–12} In the earlier stages of COVID-19 infection, however, it is likely that higher dose steroids, as typically used in management of flare of IBD, are detrimental.^{13,14}

It is therefore essential that before starting steroids if indicated for the treatment of a flare, clinicians can rule out COVID-19 infection. Instituting steroids on the basis of increased diarrhoeal symptoms on the assumption of it being a flare is counterproductive and more likely to result in poorer outcomes. In this difficult period, we urge policymakers in the UK to enable access to COVID-19 testing for such patients. This would facilitate rational and less challenging decision making and would almost certainly reduce inadvertent short-term and long-term repercussions of this pandemic to our patients.

Contributors All authors contributed equally to this opinion piece.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.



© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Quraishi MN, Cooney R, Brookes MJ, et al. *Frontline Gastroenterology* 2020;**11**:330–331.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD

Mohammed Nabil Quraishi <http://orcid.org/0000-0003-2338-8397>

REFERENCES

- 1 European Crohn's and colitis organisation. Available: <https://ecco-ibd.eu/publications/covid-19.html> [Accessed 19 Mar 2020].
- 2 Mao R, Liang J, Shen J, *et al.* Implications of COVID-19 for patients with pre-existing digestive diseases. *Lancet Gastro Hep* 2020. doi:10.1016/S2468-1253(20)30076-5. [Epub ahead of print: 11 Mar 2020].
- 3 Surveillance epidemiology of coronavirus under research exclusion (SECURE-IBD). Available: <https://covidibd.org/> [Accessed 19 Mar 2020].
- 4 Molodecky NA, Soon IS, Rabi DM, *et al.* Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012;142:46–54.
- 5 Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. *Frontline Gastroenterol* 2015;6:169–74.
- 6 Pan L, Mu M, Ren HG, *et al.* Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *Am J Gastroenterol* 2020.
- 7 Study from The American Journal of Gastroenterology Reveals Diarrhea is a Prominent Symptom of COVID-19 [news release]. American College of Gastroenterology's website. Available: <https://gi.org/wp-content/uploads/2020/03/ACG-AJG-Media-Statement-COVID19-Hubei-Pan-et-al-FINAL-03182020.pdf> [Accessed 19 Mar 2020].
- 8 Public Health England. Available: <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection> [Accessed 19 Mar 2020].
- 9 Lau SKP, Lau CCY, Chan K-H, *et al.* Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. *J Gen Virol* 2013;94:2679–90.
- 10 de Jong MD, Simmons CP, Thanh TT, *et al.* Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nat Med* 2006;12:1203–7.
- 11 Liu Q, Zhou Y-hong, Yang Z-qiu. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cell Mol Immunol* 2016;13:3–10.
- 12 Short KR, Veeris R, Leijten LM, *et al.* Proinflammatory cytokine responses in Extra-Respiratory tissues during severe influenza. *J Infect Dis* 2017;216:829–33.
- 13 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473–5.
- 14 Ni Y-N, Chen G, Sun J, *et al.* The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. *Crit Care* 2019;23:99.